Hypertension

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
Wednesday, April 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

Retrieved on: 
Wednesday, April 3, 2024
Cardiology, Diagnosis, Xi'an Jiaotong University, Speech, Gene, Congress, Research, Science, Doctor of Philosophy, Marketing, Overseas, International Medical Congress, Psychiatry, Molecular biology, Notifiable disease, SCO, Hypertension, Shanghai Cooperation Organisation, Medicine, Pharmaceutical industry

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".

Key Points: 
  • BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".
  • Alymkadyr Beishenaliev, Minister of Health of the Kyrgyz Republic, Janesh Kane, Deputy Secretary General of the SCO, and 400 medical professionals, academicians and world-renowned scientists attended the congress.
  • At this congress, Tianlong invited Professor Kou Huijuan from the Department of Cardiology of the Second Affiliated Hospital of Xi'an Jiaotong University to give a speech.
  • Tianlong's participation in the medical conferences facilitated international exchange and cooperation in the medical field.

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

Retrieved on: 
Wednesday, April 3, 2024
Cardiology, Diagnosis, Xi'an Jiaotong University, Speech, Gene, Congress, Research, Science, Doctor of Philosophy, Marketing, Overseas, International Medical Congress, Psychiatry, Molecular biology, Notifiable disease, SCO, Hypertension, Shanghai Cooperation Organisation, Medicine, Pharmaceutical industry

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".

Key Points: 
  • BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".
  • Alymkadyr Beishenaliev, Minister of Health of the Kyrgyz Republic, Janesh Kane, Deputy Secretary General of the SCO, and 400 medical professionals, academicians and world-renowned scientists attended the congress.
  • At this congress, Tianlong invited Professor Kou Huijuan from the Department of Cardiology of the Second Affiliated Hospital of Xi'an Jiaotong University to give a speech.
  • Tianlong's participation in the medical conferences facilitated international exchange and cooperation in the medical field.

Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health

Retrieved on: 
Tuesday, April 2, 2024
Diabetes, Prediabetes, Hypertension

NEW YORK, April 2, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.
  • The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1.
  • The second employer, a national professional services company, selected Dario's full suite of solutions to deliver personalized support for employees living with cardiometabolic health conditions and commonly co-occurring musculoskeletal and behavioral health needs.
  • "The need for an integrated approach to address the most common and chronic health needs continues to drive demand for Dario's multi-chronic solutions.

China Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at Home

Retrieved on: 
Saturday, March 30, 2024
Quanta, Cloud, Diagnosis, Sleep, UPPP, Sleep apnea, Certification, Sudden death, Intracerebral hemorrhage, Otorhinolaryngology, Patient, Heart rate, Stroke, Research, AI, Record, Snoring, Society, OSAS, Hospital, Electroencephalography, Automation, Hypertension, Respiratory system, Family, Food, Physician, ECG, Apnea, Pharmaceutical industry

TAICHUNG, March 30, 2024 /PRNewswire/ -- Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, which can lead to life-threatening conditions such as heart disease, hypertension, intracerebral hemorrhage, stroke, and even sudden death during night-time in severe cases. Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home. More than 100 patients have been in clinical trials of iDREAM. With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.

Key Points: 
  • Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home.
  • With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.
  • iDREAM , the home-based sleep detection system, detects ECG change from OSAS episodes and determines severity using its deep learning methodology.
  • It demonstrates 92.7% and 93.2% accuracy for sleep apnea and wake-up events (interruption of sleep from apnea), and 95.8% accuracy for defining severe OSAS (30 episodes per hour).

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, March 28, 2024
Nexus, DTS, Sanofi, Growth, Partnership, Diabetes, Webcast, Ratio, Research, Acquisition, Diabetes Technology Society, Prediabetes, Traction, Depreciation, GAAP, Hypertension, Total, Medicine, Marketing, Video game

NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.

Key Points: 
  • NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
  • Gross profit as a percentage of revenues decreased to 3.7% in the fourth quarter of 2023, from 40.1% in the fourth quarter of 2022, and 17.3% in the third quarter of 2023.
  • Total operating expenses for the fourth quarter ended December 31, 2023, were $14.3 million compared with $11.7 million for the fourth quarter ended December 31, 2022, and $16.1 million for the third quarter of 2023, an increase of $2.6 million, or 22.2%, compared to the fourth quarter of 2022, and a decrease of $1.8 million, or 11.2%, compared to the third quarter of 2023.
  • Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the fourth quarter of 2023 were $9.9 million compared to $10 million for the fourth quarter of 2022, and $10.9 million for the third quarter of 2023.

CVS Health® invests more than $3M in organizations improving health outcomes in Phoenix

Retrieved on: 
Wednesday, March 27, 2024
Blood pressure, Depression, Ozone, Overweight, Health, FQHC, Organization, Climate change, CVS, Project, Mental, Native Americans, Diabetes, Pharmacy, Conditional sentence, Patient, Education, CVS Pharmacy, Transport, Death, Quality of life, Senior, Bone density, City, CVS Health, Corporate social responsibility, Body mass index, Smoking, Osteoporosis, Suicide, American Lung Association, Cholesterol, Air pollution, Valleywise Health, Hypertension, Nursing

This announcement was made during a Project Health event in Phoenix and included CVS Health leaders, community organizations and local officials.

Key Points: 
  • This announcement was made during a Project Health event in Phoenix and included CVS Health leaders, community organizations and local officials.
  • "No two communities are the same," said Sheryl Burke, Senior Vice President of Corporate Social Responsibility and Chief Sustainability Officer at CVS Health.
  • With 65% of South Phoenix residents overweight or obese and knowing that 80% of health care costs are primarily due to preventable chronic diseases, CVS Health saw an opportunity to tailor its Health Zones initiative in Phoenix to address the high levels of diabetes and hypertension.
  • In addition to these new grants, CVS Health will offer free health screenings to the Phoenix community through its Project Health program, starting in March.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

RWJBarnabas Health and Rutgers Health to Showcase Breakthrough Cardiology Data at the American College of Cardiology Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
CMR, TME, FACC, National Health Interview Survey, Research, Obesity, Hypertension, MRI, Cooperman Barnabas Medical Center, Facial muscles, HIV, Diabetes, Risk, National Health, Patient, Stroke, RWJBarnabas Health, Community Medical Center, Mortality, Aortic stenosis, American College of Cardiology, Telehealth, Faculty, New Jersey Medical School, NHIS, Abstract, American College, Smoking, LVDD, Rutgers University, Division, TAVR, Collection, Jersey City Medical Center, ACC, YPLL, Acute coronary syndrome, Health, Meta-analysis, Dietary supplement

WEST ORANGE, N.J., March 25, 2024 /PRNewswire/ -- Physician-scientists from RWJBarnabas Health and Rutgers Health will present an extensive portfolio of innovative cardiovascular data from their clinical research program at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Atlanta, Georgia on April 6 to 8, 2024. A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.

Key Points: 
  • A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.
  • RWJBarnabas Health cardiac centers of excellence are nationally recognized for patient care and superior outcomes, including being named as one of Becker's top 100 Great Heart Programs in the country and recognized by American College of Cardiology as a Proven Quality Program.
  • Prior studies suggest that distinct patient subgroups with aortic stenosis may experience left ventricular systolic and diastolic dysfunction before the development of severe AS.
  • The study included patients who had received an angiogram done within 14 days of the CMR.